Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Exec appointment
confidence 75%
filed 2026-09-08
Item 5.02
The filing discloses the appointment of Rob Myers, M.D., as Chief Medical Officer effective September 21, 2026, to succeed Joanne Quan, M.D. While the section also describes Dr. Quan's departure and associated severance arrangements, the principal announced action is the appointment of a new CMO to a named executive officer role. The appointment of a C-suite executive is material to investors assessing company leadership and continuity.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-08
Item 5.02
Jeffrey Bertolini was appointed Chief Operating Officer of Carlsmed, Inc., effective September 8, 2026, by the Board of Directors on September 4, 2026. The appointment includes compensatory arrangements with a salary increase to $475,000, target incentive opportunity increased to 60%, and a grant of 50,000 stock options. Bertolini was promoted from Senior Vice President of Operational Excellence and brings senior leadership experience from major medical device companies including SI-BONE, NuVasive, and US Surgical.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-08
Item 5.02
The filing discloses the appointment of Gildas Bonnier as Interim Chief Financial Officer effective September 4, 2026. Although the role is interim and a permanent CFO search is underway, the appointment of a principal financial officer is a material executive appointment that would affect investor assessment of the company's financial leadership and governance. The detailed biographical information and compensation terms ($10,000/month consulting fee) confirm this is a substantive appointment disclosure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-08
Item 5.02
The Board approved the appointment of Frank Dixon Whitworth III as President of Satellogic Inc., effective September 7, 2026. While the disclosure includes compensatory details (base salary of $400,000, performance bonus target of $240,000, and RSU grants), the principal disclosed action is the appointment of a named executive officer to a senior leadership position. The compensation terms are ancillary to the appointment itself, making exec_appointment the most salient classification.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-08
Item 5.02
The Board of Directors elected Michael J. Katz as a Class II director effective September 3, 2026, to serve until the 2027 annual meeting. This is a clear director appointment with detailed disclosure of his qualifications, including his extensive leadership experience at T-Mobile and recognition as one of Forbes' 50 most influential CMOs. Director appointments are material governance events affecting the composition and oversight of the company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-08
Item 5.02
Concentra Group Holdings Parent, Inc. announced a leadership succession involving the appointment of Tanner Newton as Executive Vice President and Chief Financial Officer effective November 1, 2026, concurrent with the promotion of Matthew DiCanio to President and CEO and Keith Newton to Executive Chairman.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-09-08
Item 5.02
Jack Weingart was appointed Chairperson of the T-POP Board effective September 6, 2026, in addition to his existing roles as CEO and board member. While Todd Sisitsky's concurrent resignation as Chairperson is disclosed, the principal action disclosed is Weingart's appointment to the chair role, making this an exec_appointment event. The appointment of a CEO to chair is material to investors' understanding of governance and leadership structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-04
Item 5.02
Laird Superfood appointed Mark Johnson as Chief Financial Officer effective October 1, 2026. Johnson brings 25+ years of finance leadership experience in CPG companies and will serve as the company's principal financial officer and principal accounting officer reporting to the CEO, with a base salary of $375,000, bonus eligibility, and severance terms.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-03
Item 5.02
Keith Stauffer was appointed as Vice President, Global Finance effective September 7, 2026, and Chief Financial Officer effective November 2, 2026. The appointment includes comprehensive compensation arrangements including base salary, equity awards, and a sign-on bonus.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-09-03
EX-99.1
AC Immune SA held an Extraordinary General Meeting to propose the election of Tom Graney to the Board of Directors and the Audit and Finance Committee. Graney, who previously served on the board from 2016–2023, brings significant biotech and CFO/CEO experience to the company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-03
Item 5.02
Halide Alagoz was appointed Chief Operating & Product Officer, effective November 29, 2026, with expanded responsibilities including AI strategy and architecture & design, following Bob Ranftl's retirement as Chief Operating Officer. This represents a significant change in the Company's operational leadership structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-09-03
Item 5.02
The filing discloses the appointment of three new directors (Richard Shorten, Todd Larsen, and Lok Lee) effective September 3, 2026, to fill vacancies created by three resignations. While both departures and appointments occur, the principal disclosed action centers on the Board's appointment of the new directors and their committee assignments. The appointment of Richard Shorten is particularly material given his significant related-party transactions: he controls Silvermine Capital Advisors (40% owner of GlobalStake), which serves as investment adviser to Comstock MultiChain Fund—a current shareholder that participated in prior PIPEs and has ongoing financial relationships with the Company totaling millions in proceeds and warrant exercises.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-09-03
Item 5.02
Ragnar Udd has been appointed President and Chief Executive Officer of Albemarle effective February 1, 2027, and will join the Board of Directors. The appointment follows a comprehensive Board succession planning process and includes detailed compensatory arrangements (base salary $1.3M, sign-on bonus $1.4M, make-whole equity awards of $11M, and 2027 LTI awards of $7.5M). J. Kent Masters transitions from CEO to Executive Chairman as part of a well-defined succession plan.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-03
Item 5.02
Richard R. Fabian was appointed President of Profound Medical effective September 1, 2026, succeeding Mathieu Burtnyk who transitioned to Chief Technology Officer. Fabian brings 29+ years of healthcare industry experience, including prior roles as CEO of FUJIFILM Sonosite and executive positions at Philips Healthcare and STERIS, with a compensation package of $550,000 base salary, up to 100% bonus, 200,000 RSUs, and 475,000 options.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-03
Item 5.02
Joseph M. Miller has been appointed as Chief Financial Officer of LB Pharmaceuticals effective September 2, 2026. The appointment includes compensatory arrangements comprising a base salary of $530,000, a target bonus of 40%, and an equity option grant of 200,000 shares. Miller brings extensive biopharmaceutical finance experience and will support the company through a potentially transformative period including pivotal clinical trial results and potential commercialization of LB-102.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-03
Item 5.02
CarGurus announced the appointment of Matthew Mandel as Chief Financial Officer, effective October 19, 2026, with a compensation package including a $450,000 base salary, $450,000 target bonus, $250,000 sign-on bonus, and $5.5 million in RSUs. Mandel succeeds Jason Trevisan, who served as interim CFO since March 2025.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-03
Item 5.02
T-Mobile appointed Jessica Uhl as Chief Financial Officer Designate effective mid-September 2026, with transition to CFO in February 2027, succeeding Peter Osvaldik. The appointment includes detailed compensation terms: $975,000 base salary, $1M sign-on bonus, and $9.525M in long-term incentive awards.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-03
Item 5.02
David Buss was appointed as Senior Vice President and Chief Operating Officer effective August 31, 2026. Mr. Buss brings over 30 years of transportation and logistics leadership experience, including prior CEO roles at DB Schenker, and will receive a base salary of $250,000 with severance provisions and incentive compensation eligibility.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 85%
filed 2026-09-03
The filing announces the appointment of Dr. Jialin Lu as an independent director and member of three board committees, with designation as chairperson of the nominating and corporate governance committee, effective September 3, 2026. While the filing also discloses the resignation of Ms. Sha Ye, the principal disclosed action is the appointment of a new director to a material governance role. Board composition changes affecting independent director representation and committee leadership are material to investors assessing governance quality.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-03
Item 5.02
Byrna Technologies appointed Matthew McBrady, Ph.D. to its Board of Directors, effective August 29, 2026. Dr. McBrady brings substantial experience from his tenure on Axon Enterprise's board (2001–2014, 2016–2026), where he chaired multiple committees, combined with CFO experience at GoBrands and hedge fund/private equity investment expertise. The board was expanded from seven to eight members as part of a planned board refreshment strategy.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-03
Item 5.02
Wil W. Osborn was appointed as President and Chief Executive Officer of Federal Home Loan Bank of Des Moines, effective October 1, 2026, following a comprehensive succession planning process. The appointment includes compensation of $900,000 annual salary plus incentive awards up to 100% of base salary.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-09-03
Item 5.02
The disclosure centers on the appointment of Richard James as Controller and Chief Accounting Officer effective April 1, 2027, following Matt Simmons' announced retirement. While both a departure and appointment occur, the filing emphasizes James's appointment with detailed background and qualifications, making the appointment the principal disclosed action. The Controller/CAO role is a named executive officer position material to investors assessing financial reporting oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-09-03
Item 5.02
The filing discloses both a departure (Sofia Chernylo as Senior Vice President and Chief Accounting Officer) and an appointment (Matthew Fennewald to the same role). While both events occur, the principal focus and substantive disclosure centers on Fennewald's appointment, including his detailed background, prior roles at the Company, professional credentials (CPA), and prior experience at PwC and Crowe Horwath. The appointment of a principal accounting officer is material to investors assessing the registrant's financial reporting controls and leadership continuity.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-03
Item 5.02
David McAvoy was appointed as Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary on August 31, 2026, bringing 30+ years of biopharmaceutical legal leadership experience from roles at Eli Lilly, Endocyte, Brickell Biotech, and Teva to support the Company through VAX-31's development and anticipated commercialization.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-03
Item 5.02
UiPath announced three executive appointments: Hitesh Ramani as Chief Financial Officer (promoted from Deputy CFO and Chief Accounting Officer), Brad Brubaker as Chief Legal & Administrative Officer (expanded from Chief Legal Officer), and Yazdi Bagli as a new independent board member. Ashim Gupta transitioned from CFO to Chief Operating Officer.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-03
Item 5.02
The Board approved the appointment of Tigran Sinanyan as Chief Financial Officer and Treasurer, effective October 1, 2026. Sinanyan, who previously served as CFO from 2015–2021 and has been SVP Finance since July 2025, will receive a base salary of $475,000, target bonus of 70% of base salary, and an RSU award of $252,100, along with severance and change-of-control protections.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-09-03
Item 5.02
The filing discloses both a director departure (Paul Krause's resignation effective August 31, 2026) and a director appointment (Matt Ryan appointed to the Board effective September 1, 2026). While both events are present, the appointment of Matt Ryan is the principal forward-looking action and receives substantive disclosure including his current role as Chief Marketing and Technology Officer of Harley-Davidson, Inc., making the appointment the more salient event. Board composition changes are material to investors assessing governance and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-02
Item 5.02
The filing discloses the appointment of five Executive Vice Presidents effective September 1, 2026: Joseph M. McFarland III (Pro and Home Services), Quonta D. Vance (Stores), Seemantini Godbole (Chief Information and AI Officer), Adam D. Filipponi (Strategy and Business Development), and Jennifer E. Wilson (Chief Marketing Officer). The Company explicitly states these appointments are "designed to strengthen the execution of our Total Home strategy and position Lowe's for our next phase of growth," indicating material strategic reorganization affecting senior leadership and accountability structures.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 85%
filed 2026-09-02
EX-99.1
Ms. Li Lu has been appointed as Joint Company Secretary, Authorized Representative, and Chief Financial Officer effective September 2, 2026, replacing Ms. Qu Cong who resigned. While the announcement discloses both a departure and an appointment, the principal disclosed action is the appointment of Ms. Li to these officer roles. The appointment is material because it involves a named executive (CFO) and requires a regulatory waiver from the Hong Kong Stock Exchange due to Ms. Li's lack of formal company secretary qualifications, indicating governance significance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-02
Item 8.01
Angela M.W. Kelley has been appointed as Executive Vice President, General Counsel and Corporate Secretary, effective October 13, 2026, succeeding Randall J. Erickson.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-02
Item 7.01
Kroger announced the appointment of Mark Ibbotson as Executive Vice President and Chief Store Operations Officer, effective September 14, 2026. This is a named executive appointment to a senior leadership role overseeing critical store operations and digital transformation initiatives. The press release emphasizes his extensive retail operations experience at Walmart and Asda, making this a material executive appointment that would affect investor assessment of the company's operational leadership.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-09-02
The 6-K discloses the appointment of Mr. Bo Wang as Chief Financial Officer effective September 1, 2026, following the resignation of Mr. Mengnan Wang. While both a departure and appointment occur, the principal disclosed action is the appointment of a named executive to a C-suite role (CFO). Mr. Bo Wang's qualifications—CPA in China, 10+ years in auditing and accounting, prior experience at Arthur Andersen and as financial controller—are detailed, and the Board's formal recommendation and appointment are documented. This is material to investors as it affects the registrant's financial leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-02
Item 5.02
The filing discloses the appointment of Clay Ritchey as Chief Executive Officer and Board member, effective September 8, 2026. While the section also mentions Kevin Coop's departure as CEO, the principal disclosed action centers on the new CEO appointment with detailed employment terms including $500,000 base salary, 87.5% target bonus, and $4,000,000 in new hire equity awards. This is a material executive leadership change affecting investor assessment of company direction and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-02
Item 5.02
The Board appointed James E. Olsson as Executive Vice President, Chief Growth Officer effective September 6, 2026, with oversight of direct businesses, retail stores, merchandising, planning, global sourcing, and brand strategy. His compensation package includes a base salary of $475,000, an RSU grant of $250,000, an annual bonus target of 60%, and LTIP participation.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-09-02
Item 5.02
Aric Chang was appointed as Chief Financial Officer of American Healthcare REIT, Inc., effective October 1, 2026, succeeding Brian S. Peay who is retiring after 10 years in the role. Chang brings extensive REIT finance and capital allocation experience from Public Storage, with compensation terms including a $500,000 base salary, 100% target bonus, $1,000,000 long-term incentive award, and $310,000 sign-on bonus.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-02
Item 5.02
On August 27, 2026, Steven Tannenbaum, William J. Liquori, and William Denkin were appointed to the board of directors in connection with the IPO, with assignments to the Audit and Compensation committees. The appointments establish the company's independent director governance structure at the time of its public offering.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-02
The filing discloses the appointment of three new independent directors (Mark Schwartz, Kimi L. Ellen, and Dante W. Robinson) to Solidion's Board, increasing board size from four to seven members. The appointments are material as they strengthen the company's financial and governance expertise, and critically, the Audit Committee appointments restore Nasdaq Rule 5605(c)(2)(A) compliance, which the company had previously lost. This is a significant governance event affecting board composition and committee structure.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-09-02
The filing discloses that the Board of Directors approved the election of Benjamin Steinbruch as Chairman of the Board and that Fabio Schvartsman will assume the position of Chief Executive Officer (CEO) effective September 3, 2026. These are material executive appointments at the highest levels of the company. The disclosure is labeled "MATERIAL FACT" and filed as a 6-K, indicating the registrant itself considers this material to investors.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-09-02
Item 5.02
The filing discloses both a resignation (Vincent J. Arnone stepping down as Chairman effective September 15, 2026) and an appointment (Sharon L. Jones elected as Chairman effective September 16, 2026). While both events occur, the principal action centers on the appointment of a new Chairman to fill the vacancy, making exec_appointment the most salient classification. The change in board leadership is material to investors assessing governance and strategic direction.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-09-02
The 6-K discloses the appointment of three new directors to Basel Medical Group's board: Mr. Yang Xinwen, Ms. Cao Juan, and Mr. Frederick Hong. While two incumbent directors (Fung Keng Leong and Tan Boon Chye) departed, the principal disclosed action is the addition of three new board members with detailed biographical information and expected contributions to governance and strategic leadership. This constitutes a material executive appointment event affecting board composition and governance capabilities.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-09-02
Item 5.02
Philip J. Boeckman is appointed as Chief Legal Officer effective October 1, 2026, a named executive officer role overseeing legal functions. While Renee L. Wilm's transition to Senior Advisor represents a departure from her prior role, the principal disclosed action centers on the appointment of Boeckman to a material C-suite position. The detailed background on Boeckman's qualifications and experience underscores the significance of this appointment.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-02
Item 5.02
The filing discloses the appointment of Anish K. Shah as Vice President & Controller and principal accounting officer of Murphy USA, effective September 1, 2026. While the disclosure includes compensatory details (base salary of $360,000, bonus and equity targets, and a $25,000 sign-on bonus), the principal disclosed action is the appointment of a named executive to a key accounting and financial reporting role. This is material to investors as the principal accounting officer is responsible for financial statement preparation and internal controls.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-09-02
Item 5.02
Jeff Epstein, former Oracle CFO and current Bessemer Venture Partner with board experience at Autodesk, Twilio, and AvePoint, was appointed to Zoom's Board of Directors effective August 31, 2026, and assigned to the Audit Committee. Jonathan Chadwick's resignation from the board was also disclosed in connection with this transition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-02
Item 5.02
Dave Hulays was appointed as Senior Vice President and Chief Financial Officer of The Hershey Company effective September 2, 2026, succeeding Steven E. Voskuil who transitioned to Senior Vice President, Strategic Projects.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-09-02
Ian Tyler has been appointed as Chair of BP following an extensive search process, assuming the role immediately after serving as Interim Chair since May 2026. The appointment of a Chair is a material governance event affecting the registrant's leadership structure and board composition, and the disclosure explicitly announces this as a principal corporate action.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-02
Item 5.02
The filing discloses the appointment of Anthony Armstrong as a director of Coinbase Global, Inc., effective immediately following Board approval on September 1, 2026. The Board increased its size from nine to ten directors specifically to accommodate this appointment. While the disclosure includes standard compensation and indemnification details, the principal disclosed action is the appointment of a new director to the Board and assignment to the Audit and Compliance Committee, making this an executive appointment event material to investors.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-09-02
Item 5.02
The filing discloses the appointment of Philip J. Boeckman as Chief Legal Officer effective October 1, 2026, with detailed background on his qualifications and prior role as Partner at Cravath, Swaine & Moore LLP. While the filing also mentions Renee L. Wilm's transition to Senior Advisor, the principal disclosed action centers on the appointment of a new Chief Legal Officer, a named executive officer role. This is material to investors as it reflects a change in senior legal leadership and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-02
Item 5.02
Philip J. Boeckman is appointed as Chief Legal Officer effective October 1, 2026, a named executive officer role. While Renee L. Wilm's transition to Senior Advisor represents a departure from her prior role, the principal disclosed action centers on the appointment of Boeckman to a key C-suite position. The detailed background on Boeckman's qualifications and experience at Cravath emphasizes the significance of this appointment.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-01
Item 5.02
William W. Weatherford was appointed as a director of Raymond James Financial, Inc., effective December 15, 2026, and was also appointed to the Audit Committee and Risk Committee. The Board determined he is independent.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-01
Item 5.02
Jonathan Poole was appointed as Executive Vice President and Chief Financial Officer effective January 1, 2027. While the disclosure also mentions Charles F. Wagner, Jr. ceasing to serve as CFO, the principal action disclosed is Poole's appointment to a C-suite financial role at a major pharmaceutical company. The filing details his compensation arrangements ($750,000 base salary, 90% target bonus) and change-of-control protections, which are typical components of executive appointment disclosures under Item 5.02(a) and (e).
View raw filing on EDGAR →